Apr 18 2011
Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.
"We have been able to reactivate very quickly the core competences needed to bring this cancer vaccine opportunity developed while at Epimmune. We are now ready to discuss this opportunity with various potential partners in Europe and U.S.," said Dr. Emile Loria, Managing Director for Biotech Synergy.
"Immunotherapy is making some inroads in the treatment scheme of cancer with recent successes from Dendreon and BMS. EP-2101 is made of 10 peptides and will be a readily available, off the shelf therapeutic vaccine for the HLA-A2 population, which represents 45% of the global NSCLC patients (100,000 patients in the U.S.)," added Mike Nicolaou, who was instrumental in establishing the 10-peptide vaccine formulation.
Female firefighters face elevated breast cancer risks due to toxic exposures